Foley Partner Courtenay Brinckerhoff was quoted in an article that appeared in the August 2011 issue of Nature Biotechnology titled “US Court Bolsters Biotech Patent Protection.” Brinckerhoff discusses the outcome of Therasense vs. Becton Dickinson & Company and its significance to biotech companies. She observes that the decision offers patent holders a new basis for defeating an inequitable conduct charge, but adds that litigants are likely to continue raising the defense in order to render an entire patent unenforceable until more court decisions have rejected weaker charges of inequitable conduct.
People
Related News
13 February 2025
In the News
Gregory Husisian on USMCA Viability – 'The question is in what form?'
Foley & Lardner LLP partner Gregory Husisian assessed the viability of the U.S. – Mexico – Canada Agreement (USMCA) in the IndustryWeek article, “As Tariffs Concerns Grow, Where Is the USMCA?“
13 February 2025
In the News
Nikhil Pradhan on FDA Draft AI Drug Guidance – 'The industry is very much evolving'
Foley & Lardner LLP senior counsel Nikhil Pradhan shared insight on recent draft guidance from the U.S. Food and Drug Administration's in the MedCentral article, "FDA Draft Guidance Addresses Drug Submissions that Use AI Data."
12 February 2025
In the News